Menu
Search icon
  1. Home Page
    2. ›
  2. Counties
    3. ›
  3. New York
    4. ›
  4. 10013
    5. ›
  5. NEW YORK GENOME CENTER, INC.

NEW YORK GENOME CENTER, INC.

Company claim

Is this your business?

Get access!

Company Details

Name: NEW YORK GENOME CENTER, INC.
Jurisdiction: New York
Legal type: FOREIGN NOT-FOR-PROFIT CORPORATION
Status: Active
Date of registration: 19 Aug 2010 (15 years ago)
Entity Number: 3986897
ZIP code: 10013
County: New York
Place of Formation: Delaware
Address: 101 avenue of the americas, NEW YORK, NY, United States, 10013

DOS Process Agent

Name Role Address
the corporation DOS Process Agent 101 avenue of the americas, NEW YORK, NY, United States, 10013

Agent

Name Role
REGISTERED AGENT REVOKED Agent

Commercial and government entity program

The The Commercial And Government Entity Code (CAGE) is assigned by the Department of Defense's Defense Logistics Agency (DLA) and represents your company's physical address for GSA's mailings, payments, and administrative records.

Note: A CAGE Code enables a company to contract with the U.S. government, allowing bid on government contracts and to receive government payments. Also for business this means that it's a Verified business entity and Has a validated physical address.

CAGE number:
5P5D4
Status:
Active
Type:
Non-Manufacturer
CAGE Update Date:
2024-08-08
CAGE Expiration:
2029-08-08
SAM Expiration:
2025-08-07

Contact Information

POC:
KHULANGOO G. RIZAJ
Phone:
+1 646-977-7000
Fax:
+1 347-875-4100

Form 5500 Series

Employer Identification Number (EIN):
800631734
Plan Year:
2023
Number Of Participants:
198
Sponsors Telephone Number:
6469777000
File:
View File
Plan Year:
2020
Number Of Participants:
169
Sponsors Telephone Number:
6469777000
File:
View File
Plan Year:
2019
Number Of Participants:
183
Sponsors Telephone Number:
6469777000
File:
View File
Plan Year:
2018
Number Of Participants:
182
Sponsors Telephone Number:
6469777000
File:
View File

History

Start date End date Type Value
2019-01-28 2021-04-12 Address 28 LIBERTY ST., NEW YORK, NY, 10005, USA (Type of address: Registered Agent)
2019-01-28 2022-03-23 Address 28 LIBERTY ST., NEW YORK, NY, 10005, USA (Type of address: Service of Process)
2010-08-19 2019-01-28 Address 111 EIGHTH AVENUE, NEW YORK, NY, 10011, USA (Type of address: Registered Agent)
2010-08-19 2019-01-28 Address 111 EIGHTH AVENUE, NEW YORK, NY, 10011, USA (Type of address: Service of Process)

Filings

Filing Number Date Filed Type Effective Date
220323003789 2022-03-23 CERTIFICATE OF CHANGE BY ENTITY 2022-03-23
210412000121 2021-04-12 CERTIFICATE OF CHANGE 2021-04-12
SR-55260 2019-01-28 CERTIFICATE OF CHANGE 2019-01-28
SR-55261 2019-01-28 CERTIFICATE OF CHANGE 2019-01-28
100819000869 2010-08-19 APPLICATION OF AUTHORITY 2010-08-19

USAspending Awards / Contracts

Procurement Instrument Identifier:
75N91025D00006
Link:
View Award on USAspending website
Award Or Idv Flag:
IDV
Action Obligation:
0.00
Base And All Options Value:
149974285.00
Awarding Agency Name:
Department of Health and Human Services
Performance Start Date:
2025-01-13
Description:
THE PURPOSE OF THIS CONTRACT IS TO ACQUIRE GENOME CHARACTERIZATION CENTER (GCC) SERVICES CONSISTING OF LARGE-SCALE, HIGH- RESOLUTION, AND COMPREHENSIVE SEQUENCING AND ARRAY PLATFORMS. THE SEQUENCING AND ARRAY PLATFORMS INCLUDE WHOLE EXOME SEQUENCING
Naics Code:
541380: TESTING LABORATORIES AND SERVICES
Product Or Service Code:
B529: SPECIAL STUDIES/ANALYSIS- SCIENTIFIC DATA
Procurement Instrument Identifier:
75N92024F00001
Link:
View Award on USAspending website
Award Or Idv Flag:
AWARD
Award Type:
DELIVERY ORDER
Action Obligation:
4529520.00
Base And Exercised Options Value:
4529520.00
Base And All Options Value:
0.00
Awarding Agency Name:
Department of Health and Human Services
Performance Start Date:
2024-09-23
Description:
NHLBI TRANS-OMICS FOR PRECISION MEDICINE (TOPMED) FOR THE CENTRALIZED OMICS RESOURCE (CORE) - RNA-SEQ - 2024 TASK ORDER
Naics Code:
541380: TESTING LABORATORIES AND SERVICES
Product Or Service Code:
B599: SPECIAL STUDIES/ANALYSIS- OTHER
Procurement Instrument Identifier:
75N92023F00002
Link:
View Award on USAspending website
Award Or Idv Flag:
AWARD
Award Type:
DELIVERY ORDER
Action Obligation:
0.00
Base And Exercised Options Value:
0.00
Base And All Options Value:
0.00
Awarding Agency Name:
Department of Health and Human Services
Performance Start Date:
2023-09-28
Description:
NHLBI TRANS-OMICS FOR PRECISION MEDICINE (TOPMED) FOR THE CENTRALIZED OMICS RESOURCE (CORE) - RNA-SEQ
Naics Code:
541380: TESTING LABORATORIES AND SERVICES
Product Or Service Code:
B599: SPECIAL STUDIES/ANALYSIS- OTHER

USAspending Awards / Financial Assistance

Date:
2024-09-24
Link:
View on USAspending
Awarding Agency Name:
Department of Health and Human Services
Transaction Description:
STATISTICAL METHODS FOR CHARACTERIZING MOLECULAR MECHANISMS OF HUMAN TISSUE DEVELOPMENT AND DISEASE - PROJECT SUMMARY THE UNIQUE BIOSPECIMENS AND DATA FROM THE DEVELOPMENTAL GTEX (DGTEX) PROJECT CREATE AN EXCITING OPPORTUNITY AND NEED FOR NOVEL METHODS DEVELOPMENT. IN THIS PROJECT, WE PROPOSE TO DEVELOP A SET OF STATISTICAL METHODS AND ANALYTICAL APPROACHES THAT ARE DESIGNED TO EXTRACT INSIGHTS INTO HUMAN AND NON-HUMAN PRIMATE DEVELOPMENT FROM THE MULTI-MODAL AND MULTI-TISSUE DATA FROM DGTEX POST-MORTEM DONORS. ANALYSIS OF THE DGTEX DATA REQUIRES STATISTICAL MODELS THAT CAN TAKE ADVANTAGE OF THE RICH STRUCTURE AND DIVERSITY OF THE DATA ACROSS AGES AND MODALITIES, WHILE ADDRESSING SOME OF THE INHERENT CHALLENGES. MODELS EXPLICITLY INFORMED BY AGE CAN CAPTURE DEVELOPMENTAL TRAJECTORIES OF GENE REGULATION, GENETIC EFFECTS, AND TISSUE STRUCTURE. THE RANGE OF DATA MODALITIES ALSO CREATES AN OPPORTUNITY FOR NOVEL METHODS TO CAPTURE ADDITIONAL EFFECTS AND IMPROVED RESOLUTION AT THE CELL-TYPE, ISOFORM, AND STRUCTURAL LEVELS. HOWEVER, THESE DATA ARE ALSO INHERENTLY COMPLEX, REPRESENTING A MIXTURE OF CELL TYPES ALONG WITH BIOLOGICAL AND TECHNICAL NOISE. THE AMBITIOUS STUDY DESIGN OF DGTEX ALSO COMES WITH CHALLENGES OF DONOR RECRUITMENT THAT LIMIT SAMPLE SIZE. THE METHODS PROPOSED HERE ARE DESIGNED TO LEVERAGE THE BENEFITS OF TEMPORAL MULTI-MODAL DATA, WHILE ADDRESSING DATA COMPLEXITY AND LIMITED SAMPLE SIZE. IN OUR FIRST AIM, WE WILL ANALYZE TRANSCRIPTOME VARIATION ACROSS THE HUMAN LIFESPAN, WITH IMPROVED TRANSCRIPT ANNOTATION AND NEW METHODS TO CHARACTERIZE HOW GENE EXPRESSION, ALTERNATIVE SPLICING AND CELL TYPE COMPOSITION CHANGE DURING DEVELOPMENT AND HOW THEY CONTRIBUTE IN DRIVING PHENOTYPIC CHANGE. SECONDLY, WE WILL USE MULTI-MODAL DATA FROM GTEX TO CAPTURE CHANGES IN GENE REGULATORY NETWORKS DURING DEVELOPMENT. FROM THE DGTEX HISTOLOGY IMAGES AND SPATIAL TRANSCRIPTOMICS DATA WE WILL MODEL DEVELOPMENTAL TRAJECTORIES OF TISSUE STRUCTURES, AND DESCRIBE THEIR MOLECULAR CHARACTERISTICS AS WELL AS ROLE IN DISEASE. IN OUR THIRD AIM WE WILL MAP AND CHARACTERIZE GENETIC REGULATORY VARIATION IN DGTEX AND APPLY PREDICTIVE MODELS FOR IMPROVED PREDICTIONS OF REGULATORY VARIANTS IN PEDIATRIC TISSUES. IN ADDITION TO EMPOWERING BIOLOGICAL DISCOVERY, THIS WORK HAS THE POTENTIAL TO UNCOVER DISEASE RISK FACTORS AND MECHANISMS THAT ORIGINATE OR MANIFEST DURING EARLY LIFE.
Obligated Amount:
1799133.00
Face Value Of Loan:
0.00
Total Face Value Of Loan:
0.00
Date:
2024-09-23
Link:
View on USAspending
Awarding Agency Name:
Department of Health and Human Services
Transaction Description:
PRIVACY PRESERVATION IN TRANSCRIPTOMIC DATA ANALYSIS - PROJECT SUMMARY UNDERSTANDING THE MECHANISM BEHIND CELLULAR ACTIVITIES REQUIRES LARGE-SCALE MINING OF GENETIC AND TRANSCRIPTOMIC OBSERVATIONS FROM LARGE AMOUNTS OF HUMAN DATA. WIDESPREAD AND EASY ACCESS TO SUCH DATA IS IMPERATIVE TO MAKE BIOLOGICAL CONNECTIONS BETWEEN GENES AND DISEASES. HOWEVER, THERE IS A DIRECT CONFLICT BETWEEN PROTECTING THE PRIVACY OF PATIENTS AND RESEARCH PARTICIPANTS AND BROAD SHARING OF GENETIC AND TRANSCRIPTOMIC DATA FOR BIOMEDICAL ADVANCES. IN ORDER TO ADDRESS THESE PRIVACY CONCERNS DURING TRANSCRIPTOMIC ANALYSIS, WE PROPOSE TO TAKE ADVANTAGE OF CRYPTOGRAPHIC APPROACHES THAT ENABLE DIRECT COMPUTATIONS ON ENCRYPTED DATA WITHOUT REVEALING THE SENSITIVE INFORMATION IN THEM. WE WILL CREATE AN EVOLVING AND MODULAR TOOL SUITE TO PRESERVE PRIVACY; THIS SUITE WILL HAVE THE ABILITY TO BE ADOPTED TO NEW DATA MODALITIES AND ANALYSIS NEEDS AS THEY ARISE. IN PARTICULAR, WE PROPOSE TO DEVELOP A SERIES OF TOOLS THAT CAN QUANTIFY THE BULK TRANSCRIPT AND SINGLE-CELL GENE EXPRESSION AND PERFORM EQTL MAPPING ON THE ENCRYPTED GENOTYPES IN A SHARED SERVER AND CLOUD SETTING. THE PROPOSED TOOLS WILL HELP PREVENT FUTURE CATASTROPHIC PRIVACY LEAKS, WHICH MAY RESULT IN A LOSS OF ACCESS TO ALL MEDICALLY ACTIONABLE DATA. OUR LONG-TERM GOAL IS TO DEMOCRATIZE DATA ACCESS FOR ALL RESEARCHERS AND CREATE TRUST BETWEEN PATIENTS AND RESEARCHERS, THUS INCREASING PARTICIPATION IN STUDIES.
Obligated Amount:
855711.00
Face Value Of Loan:
0.00
Total Face Value Of Loan:
0.00
Date:
2024-09-05
Link:
View on USAspending
Awarding Agency Name:
Department of Health and Human Services
Transaction Description:
2/5 CLINICAL OUTCOME PREDICTION OF PSYCHOSIS FROM ELECTRONIC HEALTH RECORDS (COPPER) - PROJECT SUMMARY CLINICAL PREDICTORS ARE NOW FIRMLY INCORPORATED INTO ROUTINE STANDARD-OF-CARE IN MANY FIELDS OF MEDICINE, IN CONTRAST WITH PSYCHIATRY WHERE QUANTITATIVE PREDICTORS THAT GUIDE CLINICAL DECISION-MAKING REMAIN EXTREMELY LIMITED. PSYCHOSIS-RELATED DISORDERS ARE RESPONSIBLE FOR A SUBSTANTIAL PUBLIC HEALTH BURDEN, FOR WHICH THERE ARE SIGNIFICANT UNMET NEEDS THAT WOULD BE SUBSERVED BY CLINICAL PREDICTORS. FOR EXAMPLE, LONG-TERM OUTCOMES VARY WIDELY AND IDENTIFYING INDIVIDUALS WITH POOR OR ADVANTAGEOUS FUTURE OUTCOMES WOULD HELP TO OPTIMIZE TREATMENT PLANNING AND RESOURCE ALLOCATION. FURTHERMORE, ANTIPSYCHOTICS ARE ASSOCIATED WITH ADVERSE SIDE EFFECTS, SUCH AS INCREASED RISK OF DIABETES. IN THIS APPLICATION, WE PROPOSE TO USE MACHINE LEARNING APPROACHES TO BUILD PREDICTORS AND IDENTIFY SUBTYPES OF CLINICAL OUTCOMES AMONG INDIVIDUALS WITH SCHIZOPHRENIA, THROUGH INTEGRATION OF LONGITUDINAL ELECTRONIC HEALTH RECORDS (EHRS), DIMENSIONAL PHENOTYPING, AND GENETIC ANALYSES. WE WILL ALSO EXPLORE THE PSYCHOSOCIAL AND ETHICAL IMPLICATIONS OF PSYCHIATRIC CLINICAL PREDICTORS. OUR LONG-TERM OBJECTIVE IS TO ADVANCE THE GOALS OF PRECISION PSYCHIATRY TO ACHIEVE INDIVIDUALIZED TREATMENT PLANNING, OUTCOME MONITORING, AND PREVENTIVE INTERVENTIONS. WE PROPOSE THE FOLLOWING SPECIFIC AIMS: AIM 1: LEVERAGE TWO INDEPENDENT EHR DATABASES FOR OUTCOME PREDICTION AND SUB-CLASSIFICATION OF PSYCHOSIS-RELATED DISORDERS. (A) WE WILL USE THE LONGITUDINAL PSYCKES AND MARKETSCAN DATABASES TO BUILD MACHINE LEARNING-BASED INDIVIDUAL-LEVEL PREDICTION MODELS TO FORECAST THE ONSET OF FOUR MAJOR PROGNOSTIC OUTCOMES: TREATMENT RESPONSE (ANTIPSYCHOTIC RESISTANCE), ILLNESS SEVERITY (LONG-TERM HOSPITALIZATION), MEDICAL COMORBIDITY (DIABETES), AND DIAGNOSTIC TRANSITION FROM A PSYCHOSIS-RELATED DISORDER TO SCHIZOPHRENIA. (B) WE WILL PERFORM COHORT-LEVEL ANALYSES USING UNSUPERVISED METHODS TO DISCOVER NOVEL PSYCHOSIS-RELATED DIAGNOSIS AND PROGNOSIS SUBTYPES. AIM 2: ENHANCE PREDICTIVE MODELING THROUGH DIMENSIONAL PHENOTYPING AND WHOLE GENOME SEQUENCING. (A) WE WILL RECRUIT N = 10,000 PATIENTS WITH SCHIZOPHRENIA FROM THE PSYCKES DATABASE POPULATION FOR ENRICHED DATA COLLECTION: 1) DIMENSIONAL PHENOTYPING (COGNITION, EXPOSOME, AND SOCIAL DETERMINANTS OF HEALTH), AND 2) WHOLE GENOME SEQUENCING TO ENABLE CALLING OF RARE VARIANTS, STRUCTURAL VARIANTS, AND COMMON VARIANTS (POLYGENIC RISK). (B) WE WILL INVESTIGATE THE EXTENT TO WHICH DIMENSIONAL PHENOTYPES AND GENOMIC DATA CAN IMPROVE THE MODELS DEVELOPED IN AIM 1. AIM 3: EXPLORE THE PSYCHOSOCIAL AND ETHICAL IMPLICATIONS OF PSYCHIATRIC CLINICAL PREDICTORS. (A) WE WILL SURVEY A SUBSET OF PATIENTS AND THEIR CLINICIANS REGARDING THEIR ATTITUDES TOWARDS IMPLEMENTATION OF CLINICAL OUTCOME PREDICTORS. (B) WE WILL RETURN PATHOGENIC FINDINGS TO PATIENTS THROUGH GENETIC COUNSELING AND SURVEY THE EXPERIENCE OF PATIENTS AND THEIR CLINICIANS ON THEIR EMOTIONAL REACTIONS AND PERCEPTIONS OF IMPAIRMENT, TREATABILITY, AND LIFE-PLANNING.
Obligated Amount:
784642.00
Face Value Of Loan:
0.00
Total Face Value Of Loan:
0.00
Date:
2024-07-15
Link:
View on USAspending
Awarding Agency Name:
Department of Health and Human Services
Transaction Description:
SCALABLE MULTI-ANCESTRY FUNCTIONAL GENOMICS OF BLOOD TRAITS AND CARDIOVASCULAR DISEASE - PROJECT SUMMARY CARDIOVASCULAR DISEASE (CVD) IS THE MOST COMMON CAUSE OF MORTALITY IN THE WORLD. GENOME-WIDE ASSOCIATION STUDIES (GWAS) HAVE SUCCESSFULLY IDENTIFIED NUMEROUS GENETIC VARIANTS ASSOCIATED WITH CVD. HOWEVER, MOST VARIANTS DO NOT NECESSARILY CAUSE THE OBSERVED PHENOTYPES, BUT RATHER ARE IN LINKAGE DISEQUILIBRIUM WITH THE TRULY CAUSAL VARIANTS THAT INFLUENCE DISEASE PATHOPHYSIOLOGY VIA LARGELY UNKNOWN MOLECULAR AND CELLULAR MECHANISMS. THUS, THREE CENTRAL CHALLENGES FOR CVD GWAS ARE: 1) IDENTIFYING CAUSAL VARIANTS, 2) UNDERSTANDING WHICH CELL TYPES ARE MOST RELEVANT FOR SPECIFIC VARIANTS, AND 3) IDENTIFYING THE CIS- AND TRANS-REGULATORY TARGET GENES WHOSE EXPRESSION IS MODULATED BY CVD VARIANTS. CURRENTLY, THERE IS NO CONSENSUS ON HOW BEST TO IDENTIFY RELEVANT CELL TYPES AND TARGET GENES. FURTHERMORE, EFFORTS TO CONNECT SPECIFIC NONCODING VARIANTS TO TARGET GENES, SUCH AS CRISPR-BASED INSERTION OF SPECIFIC VARIANTS COUPLED WITH PHENOTYPIC ASSAYS HAVE BEEN HAMPERED BY LOW THROUGHPUT. HERE, WE SEEK TO DEVELOP SCALABLE METHODS TO ADDRESS ALL THREE CENTRAL CHALLENGES FOR CVD DISEASE GWAS, WHILE LEVERAGING THE CONSIDERABLE BENEFITS OF POPULATION-SCALE, MULTI-ANCESTRY GWAS — NAMELY, IMPROVED DISCOVERY OF NOVEL GWAS LOCI AND INCREASED RESOLUTION FOR CAUSAL VARIANTS AT ALREADY KNOWN LOCI. OF THE MANY CELL TYPES AND ORGAN SYSTEMS UNDERLYING CVD PATHOPHYSIOLOGY, WE WILL FOCUS ON BLOOD-RELATED MECHANISMS, WHICH ARE CURRENTLY UNDERSTUDIED DESPITE THE IMPORTANCE OF E.G., IMMUNE RESPONSE AND COAGULATION IN CVD, DEMONSTRATED BY PRIOR WORK AND OUR PRELIMINARY DATA. IN AIM 1, WE WILL PERFORM COLOCALIZATION OF CVD AND BLOOD CELL TRAIT GWASES (AS BLOOD CELLS TRAITS ARE NATURALLY CELL-TYPE-SPECIFIC) AND PRODUCE A REFERENCE ATLAS OF 3D ENHANCER MAPS FOR 13 BLOOD CELL TYPES AND 2 ENDOTHELIAL CELL TYPES IN DONORS OF DIVERSE ANCESTRIES. IN AIM 2, WE WILL COMBINE CRISPR SCREENS AND SINGLE-CELL MULTIOMICS (STING-SEQ) IN BLOOD AND ENDOTHELIAL CELLS TO IDENTIFY CAUSAL VARIANTS AND TARGET GENES FOR CVD. WE WILL FURTHER EXTEND IT BY DEVELOPING BEESTING-SEQ, WHICH COMBINES CYTOSINE AND ADENINE BASE EDITORS WITH A MORE FLEXIBLE CRISPR ENZYME TO INSERT PRECISE SNPS. FOR BOTH STING METHODS, WE WILL USE A THOROUGHLY-VALIDATED COMPUTATIONAL APPROACH TO IDENTIFY CIS AND TRANS TARGET GENES AND REGULATORY NETWORKS. FURTHER, WE WILL DEEPLY VALIDATE TOP VARIANTS USING KEY FUNCTIONAL ASSAYS (ELECTRICAL IMPEDANCE, MIGRATION AND STRESS RESPONSE). THIS PROPOSAL TAKES AN INTERDISCIPLINARY APPROACH WITH A TEAM OF EXPERTS IN NONCODING BIOLOGY AND HIGH-THROUGHPUT SINGLE-CELL CRISPR SCREENS (SANJANA), IN GENETICS AND SYSTEMS BIOLOGY (LAPPALAINEN) AND IN CVD GWAS, CARDIOLOGY AND ENDOTHELIAL CELL FUNCTION (GUPTA). OUR INTEGRATED EXPERIMENTAL AND COMPUTATIONAL APPROACH WILL NOT ONLY REVEAL HOW GENOMIC VARIATION SHAPES CVD RISK, BUT ALSO DEVELOP A GENERALIZABLE TOOLKIT THAT LEVERAGES CUTTING-EDGE 3D GENOME MAPPING, GENE EDITING AND SINGLE-CELL PROFILING TO MAP GENE REGULATORY ELEMENTS, SPECIFIC VARIANTS AND TARGET GENES TO INFORM FUTURE CVD THERAPEUTICS.
Obligated Amount:
827665.00
Face Value Of Loan:
0.00
Total Face Value Of Loan:
0.00
Date:
2024-06-03
Link:
View on USAspending
Awarding Agency Name:
Department of Health and Human Services
Transaction Description:
SAMBAI - SOCIAL, ANCESTRY, MOLECULAR BIOLOGY ANALYSES OF INEQUITIES - SAMBAI: SOCIETAL, ANCESTRY, MOLECULAR AND BIOLOGICAL ANALYSES OF INEQUALITIES RESEARCH ABSTRACT – NEW YORK GENOME CENTER BACKGROUND PROSTATE, BREAST, AND PANCREATIC CANCERS ALL HAVE A DISPROPORTIONATELY HIGHER RATE OF AGGRESSIVE TUMOR GRADE AND EARLY ONSET IN BLACK PATIENTS, WITH RECENT SPIKES OF HIGH INCIDENCE IN WEST AFRICAN NATIONS COMPARED TO OTHER AFRICAN REGIONS. THE GENETIC BACKGROUND CORRELATIONS IMPLICATE PREDISPOSITIONS. MEMBERS OF OUR SAMBAI TEAM OF INVESTIGATORS HAVE PIONEERED GENOMICS IN CANCER DISPARITIES RESEARCH, AND OVER THE PAST TWO DECADES, WE HAVE UNCOVERED COMPELLING EVIDENCE OF DISTINCT IMMUNOLOGICAL MECHANISMS ASSOCIATED WITH GENETIC ANCESTRY. OUR SAMBAI TEAM MEMBERS HAVE DEVELOPED METHODS TO QUANTIFY ENVIRONMENTAL EXPOSURES AND INTERROGATE THE LIVED EXPERIENCES OF MARGINALIZED POPULATIONS, INCLUDING EPIGENETIC RESPONSES TO RACISM. AIMS WE WILL PARTNER WITH SCIENTISTS ACROSS THE US, AFRICA, AND THE UK TO BUILD AN UNPRECEDENTED RESOURCE, THE SAMBAI BIOBANK AND DATA REPOSITORY FOR CANCER EQUITY RESEARCH. WE WILL GENERATE A COMPREHENSIVE, ACCURATE, AND RELEVANT MEASUREMENT OF SOCIAL, ENVIRONMENTAL, GENETIC, AND IMMUNOLOGICAL FACTORS TO COMPLETE AN INTEGRATED SET OF ANALYSES TO DEFINE THE CAUSAL VS. MODIFIER RELATIONSHIPS OF DISPARATE OUTCOMES IN DIVERSE UNDERSERVED POPULATIONS. WE WILL ESTABLISH A SUSTAINABLE FRAMEWORK FOR TEAM SCIENCE APPROACHES WITH UNDER-REPRESENTED PARTNERS AND ESTABLISH BEST PRACTICES FOR COORDINATING CANCER EQUITY RESEARCH ON A GLOBAL SCALE. METHODS WE PROPOSE TO UTILIZE MULTIPLE METHODS ACROSS OUR DIFFERENT WORK PACKAGES. SOCIAL DETERMINANTS INCLUDE SELF-REPORTING SURVEYS AND DATABASE ABSTRACTIONS. EXPOSOMES UTILIZE MASS SPECTROMETRY OF PLASMA. GENOMICS WILL UTILIZE THREE SEQUENCING METHODS ON GERMLINE AND TUMOR TISSUE, INCLUDING LONG READ, SHORT/DEEP, AND ULTRA-LOW PASS WHOLE GENOME SEQUENCING. LASTLY, IMMUNOLOGICAL PROFILES WILL BE MEASURED WITH SPATIAL TRANSCRIPTOMICS AND CIRCULATING MULTIPLEX IMMUNOASSAYS. THESE DATA REQUIRE NOVEL COMPUTATIONAL FRAMEWORKS, INCLUDING CLOUD-BASED VIRTUALIZATION AND THE USE OF MACHINE LEARNING TECHNOLOGIES TO IDENTIFY NOVEL ASSOCIATIONS ACROSS THE STRATA OF SOCIAL TO SPATIAL DATA ELEMENTS AND ACROSS OUR DIVERSE GEOGRAPHIC AND ANCESTRAL SAMBAI COHORTS. UTILITY AND IMPACT WE WILL IMPROVE RESEARCH CAPACITY IN UNDER-RESOURCED ENVIRONMENTS FOR LARGE-SCALE CANCER RESEARCH AND EQUITABLE ACCESS TO DATA WITH EQUITABLE FEASIBILITY TO IMPROVE TREATMENT AND OUTCOMES. WE WILL DEFINE INTERACTIONS OF ENVIRONMENTAL EXPOSURES, SOCIAL DETERMINANTS, AND GENETIC ANCESTRY THAT DETERMINE IMMUNOLOGICAL LANDSCAPES OF PRIMARY TUMORS AND/OR CIRCULATING IMMUNOLOGICAL PROFILES IN PATIENTS OF AFRICAN DESCENT. OUR PROJECT WILL CONTRIBUTE A DATA REPOSITORY WITH 100K FEATURES/PATIENT, FOR 40,000 PATIENTS. THE IMPACT ON THIS POPULATION INCLUDES A NOVEL TRIAL DESIGN, IN COLLABORATION WITH OUR PATIENT ADVOCACY PARTNERS, TO ENSURE THAT THE SPECIFIC GENOMIC AND IMMUNOLOGICAL FEATURES WE UNCOVER BECOME PART OF TARGETED PRECISION ONCOLOGY THERAGNOSTIC OPTIONS.
Obligated Amount:
258643.00
Face Value Of Loan:
0.00
Total Face Value Of Loan:
0.00

Trademarks Section

Serial Number:
87120063
Mark:
METRONOME
Status:
REGISTERED
Mark Type:
SERVICE MARK
Application Filing Date:
2016-07-28
Mark Drawing Type:
Standard character mark
Mark Literal Elements:
METRONOME
USPTO Link:
View Trademark Status and Document Retrieval (TSDR)

Goods And Services

For:
Providing genomic sequencing and bioinformatics data warehousing and management; providing an interactive website featuring technology that enables users to access genomic research, genome sequencing and bioinformatics data; Software as a Service (SaaS) services featuring software and software tools...
First Use:
2016-01-01
International Classes:
042 - Primary Class
Class Status:
Active
Serial Number:
85820554
Status:
ABANDONED - NO STATEMENT OF USE FILED
Mark Type:
SERVICE MARK
Application Filing Date:
2013-01-10
Mark Drawing Type:
Illustration: Drawing or design without any word(s)/letter(s)/number(s)
USPTO Link:
View Trademark Status and Document Retrieval (TSDR)

Goods And Services

For:
educational services, namely, providing conferences, courses, symposia, lectures, seminars, internship programs and lab rotations in the fields of genomics, genome sequencing, bioinformatics, and genomic data management; publication of genomics, genomic sequencing, bioinformatics and genomic data ma...
International Classes:
041 - Primary Class
Class Status:
Active
For:
promoting collaboration within the scientific, research and provider communities to achieve advances in the field of genomics
International Classes:
035 - Primary Class
Class Status:
Active
For:
genomic sequencing services for medical diagnostic or treatment purposes; consultancy, information, and analysis services in the field of bioinformatics for medical diagnostic or treatment purposes; collecting, analyzing, and reporting genomic sequencing and bioinformatics information for medical di...
International Classes:
044 - Primary Class
Class Status:
Active
For:
genomics research for medical research and scientific research purposes; genome sequencing services for medical research and scientific research purposes; consultancy, information, and analysis services in the field of bioinformatics for medical research and scientific research purposes; collecting,...
International Classes:
042 - Primary Class
Class Status:
Active
Serial Number:
85820550
Status:
ABANDONED - NO STATEMENT OF USE FILED
Mark Type:
SERVICE MARK
Application Filing Date:
2013-01-10
Mark Drawing Type:
Illustration: Drawing or design without any word(s)/letter(s)/number(s)
USPTO Link:
View Trademark Status and Document Retrieval (TSDR)

Goods And Services

For:
educational services, namely, providing conferences, courses, symposia, lectures, seminars, internship programs and lab rotations in the fields of genomics, genome sequencing, bioinformatics, and genomic data management; publication of genomics, genomic sequencing, bioinformatics and genomic data ma...
International Classes:
041 - Primary Class
Class Status:
Active
For:
promoting collaboration within the scientific, research and provider communities to achieve advances in the field of genomics
International Classes:
035 - Primary Class
Class Status:
Active
For:
genomic sequencing services for medical diagnostic or treatment purposes; consultancy, information, and analysis services in the field of bioinformatics for medical diagnostic or treatment purposes; collecting, analyzing, and reporting genomic sequencing and bioinformatics information for medical di...
International Classes:
044 - Primary Class
Class Status:
Active
For:
genomics research for medical research and scientific research purposes; genome sequencing services for medical research and scientific research purposes; consultancy, information, and analysis services in the field of bioinformatics for medical research and scientific research purposes; collecting,...
International Classes:
042 - Primary Class
Class Status:
Active
Serial Number:
85820547
Status:
SECTION 8 & 15-ACCEPTED AND ACKNOWLEDGED
Mark Type:
SERVICE MARK
Application Filing Date:
2013-01-10
Mark Drawing Type:
Illustration: Drawing or design without any word(s)/letter(s)/number(s)
USPTO Link:
View Trademark Status and Document Retrieval (TSDR)

Goods And Services

For:
educational services, namely, providing conferences, courses, symposia, lectures, seminars, internship programs and lab rotations in the fields of genomics, genome sequencing, bioinformatics, and genomic data management; publication of genomics, genomic sequencing, bioinformatics and genomic data ma...
First Use:
2011-11-03
International Classes:
041 - Primary Class
Class Status:
Active
For:
promoting collaboration within the scientific, research and provider communities to achieve advances in the field of genomics
First Use:
2011-11-03
International Classes:
035 - Primary Class
Class Status:
Active
For:
genomic sequencing services for medical diagnostic or treatment purposes; consultancy, information, and analysis services in the field of bioinformatics for medical diagnostic or treatment purposes; collecting, analyzing, and reporting genomic sequencing and bioinformatics information for medical di...
First Use:
2011-11-03
International Classes:
044 - Primary Class
Class Status:
Active
For:
genomics research for medical research and scientific research purposes; genome sequencing services for medical research and scientific research purposes; consultancy, information, and analysis services in the field of bioinformatics for medical research and scientific research purposes; collecting,...
First Use:
2011-11-03
International Classes:
042 - Primary Class
Class Status:
Active
Serial Number:
85820544
Status:
SECTION 8 & 15-ACCEPTED AND ACKNOWLEDGED
Mark Type:
SERVICE MARK
Application Filing Date:
2013-01-10
Mark Drawing Type:
Illustration: Drawing or design without any word(s)/letter(s)/number(s)
USPTO Link:
View Trademark Status and Document Retrieval (TSDR)

Goods And Services

For:
educational services, namely, providing conferences, courses, symposia, lectures, seminars, internship programs and lab rotations in the fields of genomics, genome sequencing, bioinformatics, and genomic data management; publication of genomics, genomic sequencing, bioinformatics and genomic data ma...
First Use:
2011-11-03
International Classes:
041 - Primary Class
Class Status:
Active
For:
promoting collaboration within the scientific, research and provider communities to achieve advances in the field of genomics
First Use:
2011-11-03
International Classes:
035 - Primary Class
Class Status:
Active
For:
genomic sequencing services for medical diagnostic or treatment purposes; consultancy, information, and analysis services in the field of bioinformatics for medical diagnostic or treatment purposes; collecting, analyzing, and reporting genomic sequencing and bioinformatics information for medical di...
First Use:
2011-11-03
International Classes:
044 - Primary Class
Class Status:
Active
For:
genomics research for medical research and scientific research purposes; genome sequencing services for medical research and scientific research purposes; consultancy, information, and analysis services in the field of bioinformatics for medical research and scientific research purposes; collecting,...
First Use:
2011-11-03
International Classes:
042 - Primary Class
Class Status:
Active

Tax Exempt

Employer Identification Number (EIN) :
80-0631734
In Care Of Name:
% NANCY KONG
Classification:
Government Instrumentality, Title-Holding Corporation, Charitable Organization, Agricultural Organization, Board of Trade, Pleasure, Recreational, or Social Club, Fraternal Beneficiary Society, Order or Association, Voluntary Employees' Beneficiary Association (Non-Govt. Emps.), Domestic Fraternal Societies and Associations, Teachers Retirement Fund Assoc., Benevolent Life Insurance Assoc., Burial Association, Credit Union, Mutual Insurance Company or Assoc. Other Than Life or Marine, Corp. Financing Crop Operations, Supplemental Unemployment Compensation Trust or Plan, Employee Funded Pension Trust (Created Before 6/25/59), Post or Organization of War Veterans, Legal Service Organization, Black Lung Trust, Multiemployer Pension Plan, Veterans Assoc. Formed Prior to 1880, Trust Described in Sect. 4049 of ERISA, Title Holding Co. for Pensions, etc., State-Sponsored High Risk Health Insurance Organizations, State-Sponsored Workers' Compensation Reinsurance, ACA 1322 Qualified Nonprofit Health Insurance Issuers, Apostolic and Religious Org. (501(d)), Cooperative Hospital Service Organization (501(e)), Cooperative Service Organization of Operating Educational Organization (501(f)), Child Care Organization (501(k)), Charitable Risk Pool, Qualified State-Sponsored Tuition Program, 4947(a)(1) - Private Foundation (Form 990PF Filer)
Ruling Date:
2012-01
National Taxonomy Of Exempt Entities:
Health Care: Hospital, General
Deductibility:
Type of organization and use of contribution: A public charity. Deductibility Limitation: 50% (60% for cash contributions)

Determination Letters

Link:
Download file
Link:
Download file
Link:
Download file

Reviews Leave a review

This company hasn't received any reviews.

Related by officers

the corporation

SHERMAN V. ALLEN, INC. SENSUAL EXPRESSIONS INC. BRIGHT INSIGHTS GLOBAL LABS FOR GOOD, INC. WATAN DUAL EDUCATION, INC. NAYO CARES, INC. RENEGADE SOFTBALL CLUB, INC. CFLO INC. BANGLADESHI AMERICAN COMMUNITY SERVICES, INC. TRISP FOUNDATION, INC. THE LILAC HOUSE INC.

REGISTERED AGENT REVOKED

TECHSPACE NEW YORK INC. BH SALES & MARKETING, LLC KOC FUNDING CORPORATION TRANS POWER MAURITIUS DHB INC. BALDWIN REALTY CONSULTANTS, INC. SUDO COACHING LLC ARLON OPPORTUNITIES INVESTORS GP LLC KARL ALEPH INC. SHOPPINGTOWN MALL, L.P.

Related by address

101 avenue of the americas, NEW YORK, NY, United States, 10013

YY NATION INCORPORATED DELTA CAPITA, LLC

Date of last update: 27 Mar 2025

Sources: New York Secretary of State

Privacy policy Policy
About us About us
Contacts Contact us

© 2025 bizyork.com, Part of Big Data Integrated